Literature DB >> 25035779

Investigation of granulomatous prostatitis incidence following intravesical BCG therapy.

Mehmet Balasar1, Metin Doğan2, Abdulkadir Kandemir1, Hakan Hakki Taskapu1, Faruk Cicekci3, Hatice Toy4, Recai Gurbuz1.   

Abstract

UNLABELLED: In the present manuscript, we studied the incidence of granulomatous prostatitis in the prostatectomy specimen of the patients who underwent transurethral resection of the prostate (TURP) after superficial bladder cancer treatment with intravesical Bacillus Calmette-Guerin (BCG) and were diagnosed with benign prostate hyperplasia (BPH). The clinical data and histopathological specimen records of 472 patients who underwent TUR-P due to BPH diagnosis, obtained over a period of 6 years in the urology department of Private Konya Hospital, Konya, Turkey, were studied retrospectively. The cases were divided into two groups as (Group I) who did not undergo any treatment and as (Group II) who underwent BCG treatment. The frequency and the clinical course of the cases with granulomatous prostatitis were studied histopathologically. There were in total 472 patients who underwent TUR-P. Out of the 459 patients who did not undergo BCG treatment (Group I), the histopathological specimen records of 262 (57%) was BPH, of 197 (43%) BPH + chronic prostatitis. Of the second group, 13 cases underwent intravesical BCG treatment before surgical intervention due to superficial bladder CA diagnosis. In this group 4 of the cases were diagnosed as (30%) BPH, 9 as (70%) chronic prostatitis + BPH. 6 out of the 9 chronic prostatitis cases were chronic prostatitis, 2 caseous granulomatous prostatitis, 1 non-caseous granulomatous prostatitis. Granulomatous prostatitis cases should require no specific therapy.
CONCLUSION: In patients with obstruction complaints following intravesical BCG treatment, granulomatous prostatitis should also be considered and treatment plans should be made accordingly.

Entities:  

Keywords:  Granulomatous prostatitis; TUR-P; intravesical BCG immunotherapy

Year:  2014        PMID: 25035779      PMCID: PMC4100965     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

Review 1.  Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.

Authors:  M Elkabani; J N Greene; A L Vincent; S VanHook; R L Sandin
Journal:  Cancer Control       Date:  2000 Sep-Oct       Impact factor: 3.302

Review 2.  Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.

Authors:  W J Catalona; T L Ratliff
Journal:  Surg Annu       Date:  1990

3.  Granulomatous prostatitis on needle biopsy.

Authors:  J R Oppenheimer; H Kahane; J I Epstein
Journal:  Arch Pathol Lab Med       Date:  1997-07       Impact factor: 5.534

Review 4.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

5.  Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy.

Authors:  P D LaFontaine; B R Middleman; S D Graham; W H Sanders
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

Review 6.  Novel insights into the mechanism of action of intravesical immunomodulators.

Authors:  Dionisios N Mitropoulos
Journal:  In Vivo       Date:  2005 May-Jun       Impact factor: 2.155

7.  Granulomatous prostatitis: distinction among allergic, nonspecific, and post-transurethral resection lesions.

Authors:  J I Epstein; G M Hutchins
Journal:  Hum Pathol       Date:  1984-09       Impact factor: 3.466

Review 8.  Benign mimickers of prostatic adenocarcinoma.

Authors:  John R Srigley
Journal:  Mod Pathol       Date:  2004-03       Impact factor: 7.842

9.  The clinical spectrum of granulomatous prostatitis: a report of 200 cases.

Authors:  T J Stillwell; D E Engen; G M Farrow
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

10.  Granulomatous prostatitis linked to HLA-DRB1*1501.

Authors:  Richard B Alexander; Dean L Mann; Andrew A Borkowski; Marcelo Fernandez-Vina; Elena N Klyushnenkova; James Kodak; Kathleen J Propert; Marcie Kincaid
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more
  6 in total

1.  Study on different surgical approaches for acute Lumber disk protrusion combined with Cauda Equina Syndrome.

Authors:  Lianbing Shen; Liangqin Fang; Yihua Qiu; Shunming Xing; Dechun Chen; Xiang He; Jinxin Wang; Jing Lai; Guohua Shi; Jiefeng Zhang; Teng Liao; Junming Tan
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

2.  Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy.

Authors:  Masashi Matsushima; Eiji Kikuchi; Hirotaka Akita; Akira Miyajima; Mototsugu Oya; Masahiro Jinzaki
Journal:  Int J Clin Oncol       Date:  2017-02-10       Impact factor: 3.402

3.  Granulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder Cancer.

Authors:  Choon-Young Kim; Sang-Woo Lee; Seock Hwan Choi; Seung Hyun Son; Ji-Hoon Jung; Chang-Hee Lee; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-11

4.  Analysis of risk factors for post-bacillus Calmette-Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer.

Authors:  Tae Jin Kim; Young Dong Yu; Sung Il Hwang; Hak Jong Lee; Sung Kyu Hong; Sang Eun Lee; Jong Jin Oh
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

Review 5.  Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.

Authors:  Karel Decaestecker; Willem Oosterlinck
Journal:  Res Rep Urol       Date:  2015-10-23

Review 6.  Plant Bioactives and the Prevention of Prostate Cancer: Evidence from Human Studies.

Authors:  Tracey L Livingstone; Gemma Beasy; Robert D Mills; Jenny Plumb; Paul W Needs; Richard Mithen; Maria H Traka
Journal:  Nutrients       Date:  2019-09-18       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.